Literature DB >> 33958323

SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response.

Michael Markus Bonelli1, Daniel Mrak1, Thomas Perkmann2, Helmuth Haslacher2, Daniel Aletaha3.   

Abstract

Entities:  

Keywords:  B-lymphocytes; COVID-19; rituximab

Year:  2021        PMID： 33958323     DOI： 10.1136/annrheumdis-2021-220408

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  44 in total

1. 

Authors:  Maxime Auroux; Benjamin Laurent; Baptiste Coste; Emmanuel Massy; Alexandre Mercier; Isabelle Durieu; Cyrille B Confavreux; Jean-Christophe Lega; Sabine Mainbourg; Fabienne Coury
Journal:  Rev Rhum Ed Fr       Date:  2022-07-08

2.  Promising Efficacy of a Third Dose of mRNA SARS-CoV-2 Vaccination in Patients Treated with Anti-CD20 Antibody Who Failed 2-Dose Vaccination.

Authors:  Yohei Funakoshi; Kimikazu Yakushijin; Goh Ohji; Wataru Hojo; Hironori Sakai; Marika Watanabe; Akihito Kitao; Yoshiharu Miyata; Yasuyuki Saito; Shinichiro Kawamoto; Katsuya Yamamoto; Mitsuhiro Ito; Taiji Koyama; Yoshinori Imamura; Naomi Kiyota; Hiroshi Matsuoka; Yasuko Mori; Hironobu Minami
Journal:  Vaccines (Basel)       Date:  2022-06-17

3.  Longitudinal Analysis of Biologic Correlates of COVID-19 Resolution: Case Report.

Authors:  Natalie Bruiners; Valentina Guerrini; Rahul Ukey; Ryan J Dikdan; Jason H Yang; Pankaj Kumar Mishra; Alberta Onyuka; Deborah Handler; Joshua Vieth; Mary Carayannopoulos; Shuang Guo; Maressa Pollen; Abraham Pinter; Sanjay Tyagi; Daniel Feingold; Claire Philipp; Steven K Libutti; Maria Laura Gennaro
Journal:  Front Med (Lausanne)       Date:  2022-06-15

4.  Serological Response to BNT162b2 Anti-SARS-CoV-2 Vaccination in Patients with Inflammatory Rheumatic Diseases: Results From the RHEUVAX Cohort.

Authors:  Daniele Mauro; Antonio Ciancio; Claudio Di Vico; Luana Passariello; Gelsomina Rozza; Maria Dora Pasquale; Ilenia Pantano; Carlo Cannistrà; Laura Bucci; Silvia Scriffignano; Flavia Riccio; Martina Patrone; Giuseppe Scalise; Piero Ruscitti; Maria Vittoria Montemurro; Antonio Giordano; Maria Teresa Vietri; Francesco Ciccia
Journal:  Front Immunol       Date:  2022-06-17       Impact factor: 8.786

5.  Assessment of humoral and cellular immunity induced by the BNT162b2 SARS-CoV-2 vaccine in healthcare workers, elderly people, and immunosuppressed patients with autoimmune disease.

Authors:  Giacomo Malipiero; Anna Moratto; Maria Infantino; Pierlanfranco D'Agaro; Elisa Piscianz; Mariangela Manfredi; Valentina Grossi; Enrico Benvenuti; Matteo Bulgaresi; Maurizio Benucci; Danilo Villalta
Journal:  Immunol Res       Date:  2021-08-21       Impact factor: 4.505

6.  Prompt Hematological Recovery in Response to a Combination of Pegylated Interferon α-2a and Rituximab in a Profoundly Immuno-Suppressed Hairy Cell Leukemia Patient with a Mycobacterial Infection at Onset: Benefits and Drawbacks of Rapid Immune Reconstitution.

Authors:  Anna Furlan; Maria Cristina Rossi; Filippo Gherlinzoni; Piergiorgio Scotton
Journal:  Hematol Rep       Date:  2022-04-13

7.  Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study.

Authors:  Ingrid Jyssum; Hassen Kared; Trung T Tran; Anne T Tveter; Sella A Provan; Joseph Sexton; Kristin K Jørgensen; Jørgen Jahnsen; Grete B Kro; David J Warren; Eline B Vaage; Tore K Kvien; Lise-Sofie H Nissen-Meyer; Ane Marie Anderson; Gunnveig Grødeland; Espen A Haavardsholm; John Torgils Vaage; Siri Mjaaland; Silje Watterdal Syversen; Fridtjof Lund-Johansen; Ludvig A Munthe; Guro Løvik Goll
Journal:  Lancet Rheumatol       Date:  2021-12-23

8.  SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity.

Authors:  Daniel Mrak; Selma Tobudic; Maximilian Koblischke; Marianne Graninger; Helga Radner; Daniela Sieghart; Philipp Hofer; Thomas Perkmann; Helmuth Haslacher; Renate Thalhammer; Stefan Winkler; Stephan Blüml; Karin Stiasny; Judith H Aberle; Josef S Smolen; Leonhard X Heinz; Daniel Aletaha; Michael Bonelli
Journal:  Ann Rheum Dis       Date:  2021-07-20       Impact factor: 19.103

9.  Serological response to SARS-CoV-2 vaccination in multiple sclerosis patients treated with fingolimod or ocrelizumab: an initial real-life experience.

Authors:  Guerrieri S; Lazzarin S; Zanetta C; Nozzolillo A; Filippi M; Moiola L
Journal:  J Neurol       Date:  2021-06-26       Impact factor: 4.849

Review 10.  [Updated recommendations of the German Society for Rheumatology for the care of patients with inflammatory rheumatic diseases in the context of the SARS-CoV‑2/COVID‑19 pandemic, including recommendations for COVID‑19 vaccination].

Authors:  Christof Specker; Peer Aries; Jürgen Braun; Gerd Burmester; Rebecca Fischer-Betz; Rebecca Hasseli; Julia Holle; Bimba Franziska Hoyer; Christof Iking-Konert; Andreas Krause; Klaus Krüger; Martin Krusche; Jan Leipe; Hanns-Martin Lorenz; Frank Moosig; Rotraud Schmale-Grede; Matthias Schneider; Anja Strangfeld; Reinhard Voll; Anna Voormann; Ulf Wagner; Hendrik Schulze-Koops
Journal:  Z Rheumatol       Date:  2021-08       Impact factor: 1.372
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.